Core Viewpoint - Shineco, Inc. has announced a public offering of 1,869,160 shares of common stock at a price of $1.07 per share, aiming for gross proceeds of approximately $2 million before expenses [1]. Group 1: Offering Details - The public offering consists of 1,869,160 shares priced at $1.07 each, with total gross proceeds expected to be around $2 million [1]. - Underwriters have a 45-day option to purchase an additional 280,374 shares at the same public offering price [1]. - The offering is anticipated to close on July 15, 2024, pending customary closing conditions [1]. Group 2: Underwriting and Registration - EF Hutton LLC is serving as the sole book-running manager for the offering [2]. - The shares are being offered under an effective shelf registration statement filed with the SEC, which was declared effective on June 10, 2022 [2]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC [2]. Group 3: Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to enhance the quality of life [4]. - The company has developed 33 vitro diagnostic reagents and related medical devices and also produces healthy and nutritious foods [4].

Core Viewpoint - Shineco, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the offering subject to market conditions and no assurance of completion or specific terms [1]. Group 1: Offering Details - The offering includes shares of common stock and pre-funded warrants, all offered by the Company [1]. - The offering is conducted under an effective shelf registration statement on Form S-3, which was filed with the SEC and declared effective on June 10, 2022 [2]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, detailing the terms of the public offering [2][3]. Group 2: Company Overview - Shineco, Inc. focuses on providing safe, efficient, and high-quality health and medical products and services, aiming to improve the quality of life [5]. - The Company has developed 33 vitro diagnostic reagents and related medical devices and also produces and sells healthy and nutritious foods [5].

Beijing, July 11, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company") (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced it has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase its shares of common stock. All of the shares of common stock and pre-funded warrants and the shares of common stock underlying the pre-funded warrants are being offered by the Company. The offerin ...

The Company believes that its Advanced Proprietary Production Technology Provides it with a Competitive Advantage in the Sector BEIJING, July 10, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that its subsidiary, Fuzhou Meida Health Management Co., Ltd. ("Fuzhou Meida"), has entered into Distribution Agreements (the "Agreements") for its water-soluble phospholipid concentrat ...

BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a res ...

BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non-U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchase ...

BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non- U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchas ...

BEIJING, June 20, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDA: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 18, 2024, it entered into an Investment Letter of Intent (the "Investment LOI") with Beijing Oriental Meitong Technology Co., Ltd. ("Meitong Technology") whereby Shineco intends to invest $20 million in Meitong Technology in exchange for 80% of Meitong Technology's shares. The Company believes that the ...

Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 14, 2024, its 51% owned subsidiary, Shangkang Life Science and Technology (Jiangsu) Co., Ltd. (“Shangkang Life Science”) entered into a Strategic Cooperation Framework Agreement (“the Agreement”) with Turing Video (Shenzhen) Co., Ltd (“Turing Video”) to jointly develop a series of smart medical produc ...

Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 14, 2024, its 51% owned subsidiary, Shangkang Life Science and Technology (Jiangsu) Co., Ltd. ("Shangkang Life Science") entered into a Strategic Cooperation Framework Agreement ("the Agreement") with Turing Video (Shenzhen) Co., Ltd ("Turing Video") to jointly develop a series of smart medical produc ...